Apimeds Pharmaceuticals US, Inc. APUS
7.25
2.33
47.36%
as of 25 Sep
- Market cap
- $7.6M
- P/E
- 0.0×
Follow APUS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (100.13%) | (65.22%) | (7.90%) | (125.91%) |
+7 more TTM periods Free account |
|
| (84.20%) | (57.48%) | (7.31%) | (111.52%) | ||
ROIC |
(15.96%) | (11.96%) | (5.00%) | (274.01%) | |
Return on Tangible Assets |
562.41% | 2,956.78% | (180.27%) | (64.23%) | |
Free Cash Flow per Share |
(7.78) | (7.12) | (8.25) | (4.17) | |
Free Cash Flow |
(13.33) | (11.04) | (8.98) | (5.24) | |
Capital Expenditures |
(0.05) | (0.07) | (0.06) | (0.04) | |
Piotroski F-Score |
1.00 | 4.00 | 3.00 | 0.00 | |
| Other line items | |||||
Cash ROIC |
(10.74%) | (7.57%) | (5.19%) | (34.38%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | — | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.23 | 0.27 | 1.49 | 1.01 | |
Depreciation/Fixed assets |
0.88 | 0.45 | 0.11 | 0.05 | |
Capex/Depreciation |
(1.16) | (2.60) | (10.05) | (21.12) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.75) | (7.07) | (8.20) | (4.14) | |
Capex per Share |
(0.03) | (0.04) | (0.05) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates